In another study, the stimulation of uveal melanoma cells with the GPER agonist LNS8801 (under development by Linnaeus Therapeutics) also induced melanocyte differentiation markers and concomitantly upregulated p53 and p21, G2/M mitotic arrest and the disruption of the mitotic spindle [63]. Here, TP53 is linked to uveal melanoma.